

Pharmacological Target Symptoms in Autism Spectrum Disorder (ASD)


- Inattention, Impulsivity & Hyperactivity (ADHD)
- Disruptive behaviors and irritability
- Repetitive behaviors and rigidity
- Depression and anxiety
- Mood disorders and psychosis
- Sleep disturbance

ADHD: ASSESSMENT

- Diagnosed based on clinical criteria
- Relies on integration of clinical information derived from variety of sources
- Comorbidity is typical and warrants consideration
- ADHD not diagnosed with neuropsychological testing, computerized assessments, labs, EEG or brain imaging

1: REVIEW RATING SCALES AND RECORDS

- ADHD Rating Scales
- Broad-Band Rating Scales
- School Records





2: CONDUCT COMPREHENSIVE CLINICAL INTERVIEW

• DSM-5 ADHD Criteria

- Areas of Functional Impairment
- Comorbid Emotional and Behavioral Disorders
- Psychosocial Context

Clinical Interview

- Approach differs based on age of patient
- Developmental Considerations
- Preschool-aged children
- School-aged children
- Adolescents
- Neurodevelopmental Disorders (ASD)

DSM-5 Diagnostic Criteria

ADHD Inattentive Symptoms Fails to notice details, makes careless errors Trouble maintaining attention

Appears not to listen even when spoken to directly

Trouble completing tasks or following through on instructions

Difficulty with organization

Avoids activities that require sustained attention

- Loses or misplaces things
- Distracted easily by extraneous stimuli

Forgets easily

DSM-5 Diagnostic Criteria

ADHD Hyperactive-Impulsive Symptoms Frequently fidgets, taps hands/feet or squirms seated

Frequently gets out of seat Runs and climbs when inappropriate

Unable to play quietly

Frequently "on the go" as if "driven by a motor"

Talks to excess

Blurts out answers before questions are completed Trouble waiting turn or in line

Frequently interrupts or intrudes

DSM-5 Diagnostic Criteria

• Symptoms prior to age 12 years

- Present in 2 or more settings
- Symptoms interfere with functioning
- Not explained by another disorder
- 3 subtypes
- Specify
- Partial remission
- Severity (mild, moderate, severe)

3: CONFIRM OR COMPLETE MEDICAL ASSESSMENT

• Current Medical History

- Cardiac Risk Factors
- Significant Past Medical History
- Family History

Medical Assessment

- History of cardiac defects?
- Fainting or excessive SOB during exercise?
- First or second-degree family member with MI under the age of 30?
- History of Long QT syndrome or WPW?
- History of murmur or other cardiac anomalies?

4: OBTAIN EDUCATIONAL TESTING (if indicated)


- Measure Intellectual Ability
- Assess Academic Achievement



- Half of those with ADHD have other measurable learning impairments
- WPPSI (preschool IQ)
- WISC (School age IQ)
- Vineland (Adaptive functioning)
- Woodcock-Johnson Tests of Achievement, WIAT, WRAT: Tests of academic achievement
- Impediments to obtaining testing
- Schools have limited resources

ADHD: TREATMENT PLANNING

- Multimodal approaches to ADHD treatment in youth have proven successful in maximizing improved global functioning
- Pharmacotherapy is the only intervention to yield large treatment effects on core symptoms
- Optimal treatment combines meds with psychosocial intervention targeting patient-specific difficulties



DSYCHOEDUCATION Provide didactic information about ADHD, its consequences and strategies for interventions Useful to incorporate into the initial evaluation and follow-up visits Reduce stigma associated with ADHD Referral to useful resources

Resources for Families

ADD Association: <u>www.add.org</u> Children & Adults with ADD (CHADD): www.chadd.org Edge Foundation: <u>www.edgefoundation.org</u> Learning Disabilities Assn. of America (LDA): www.Ldanatl.org

INFORMATIVE WEBSITES

- AACAP Facts for Families (aacap.org) Healthy Children (healthychildren.org)
- National Institute of Mental Health (NIMH)
- US Centers for Disease Control and Prevention



School-Focused Interventions

- Section 504 Plans
- Individual Educational Programs (IEP)
- Behavioral Classroom Management
- Standardized Testing Accommodations

Patient-Focused Interventions

- Health Maintenance
- Pharmacotherapy
- Social and Peer-Related Activities
- Social Skills Training
- o Individual Therapy

ADHD PHARMACOTHERAPY

• History

- 1930s: Charles Bradley tested amphetamine on pediatric headaches
- 1944: Ritalin synthesized
- 1744. KIIGIIII synniesized
- 1954: Ritalin identified as stimulant medication • Safety
- Lots and lots of studies!
- Efficacy
 - 70 % initial response rate (based on >300 studies)

MEDICATION OPTIONS

STIMULANTS	NONSTIMULANTS	OFF-LABEL MEDS
		IR alpha-2 agonists
Methylphenidates	Atomoxetine	Buproprion
D-MPH	ER Alpha-2 agonists	Modafinil
D-Amphetamines		TCAs
Mixed Amphetamine Salts		Antipsychotics
Lisdexamfetamine		MAO Inhibitors

	phenidate (N	· · · · · · · · · · · · · · · · · · ·
Prepar	ations (FDA A	(pproved)
BRAND NAME	DOSES AVAILABLE	DOSING (may excee FDA dosing)
Ritalin	2.5, 5, 10, 20 mg	5-20 BID/TID
Methylin	2.5, 5, 10 chew; 10mg/ 5ml sol.	Children: 2.5-10 mg/ BID-TID
Focalin	2.5, 5, 10 mg	2.5-10mg/ BID
Ritalin SR	20 mg	20-60 mg QD-BID
Metadate ER	20 mg	20-60 mg QD-BID

MPH P	reparations	
Extended Release	(MPH-ER)	
Concerta	18, 27, 36, 54 mg	18-72 mg/ day
Ritalin LA	10, 20, 30, 40 mg	10-40 mg /day
Metadate CD	10, 20, 30, 40, 50, 60 mg	20-60 mg /day
Daytrana	10, 15, 20, 30 mg patch	10-30 mg/ day
Quillivant XR	25 mg/ 5mL solution	20-60 mg/ day
Focalin XR	5, 10, 15, 20, 25, 30, 35, 40 mg	10-40 mg/ day

Amphet	amine For	mulations
BRAND NAME	DOSES AVAILABLE	USUAL DOSING
IMMEDIATE RELEASE		
Dexedrine	5, 7.5, 10, 15, 20, 30 mg	2.5-40 mg QD-TID
Adderall	5, 7.5, 10, 12.5, 15, 20, 30 mg	5-40 mg QD-TID
SUSTAINED RELEASE		
Dexedrine Spansules	5, 10, 15 mg	5-40 mg/ QD-BID
EXTENDED RELEASE		
Adderall XR	5, 10, 15, 20, 25, 30 mg	Children: 10-30 mg/day Adults: 10-60 mg /day
Vyvanse	20, 30, 40, 50, 60, 70 mg	30-70 mg/ day

FDA-Approve Medications 1		nulant
Brand Name	Doses Available	Usual Dosing
NORADRENERGIC REUPTAKE INHIBITORS		
Strattera (atomoxetine)	10, 18, 25, 40, 60, 80, 100 mg	0.5 mg/ kg to 1.2-1.4 mg/ kg QD
ALPHA-2 AGONISTS		
Intuniv (guanfacine ER)	1, 2, 3, 4 mg	1-4 mg QD

0.1, 0.2 mg

0.1-.04 mg/ QD-BID

Kapvay (clonidine ER)





Medication Management

• Choosing an agent

- ${\scriptstyle \circ}$ Start with an FDA-approved medication
 - Stimulant v. Non-Stimulant?
- MPH v. AMPH?
 - MPH milder in meta-analysisAMPH may provide better coverage for
 - adults.
 - Can patient swallow pills?

Choosing an Algorithm

- Where to start?
- Inattentive v. H/I v. Combined Type
- When to change agents?
- How to change agents?
- When to change from stimulant to nonstimulant?
- How soon to increase dose if ineffective?
- When to utilize combination therapy?

		ation
MEDICATION / DOSE	# DISP / SCRIPT	PATIENT INSTRUCTIONS
OROS-MPH 18 mg	#30	First 5 days: 1 tab
	1-2 QAM AD	Second 5 days: 2 tabs
		Third 5 days: 3 tabs
D-MPH ER 5 mg	#30	First 5 days: 1 cap
Patient <25 kg	1-2 QAM AD	Second 5 days: 2 caps
		Third 5 days: 3 caps
D-MPH ER 10mg	#30	First 5 days: 1 cap
Patient >25 kg		Second 5 days: 2 caps
		Third 5 days: 3 caps


Medication Titration

	#30	First 5 days: 1 cap
(5 mg in younger) 1		insi o days. i oap
	-2 QAM AD	Second 5 days: 2 caps
		Third 5 days: 3 caps
LDX 20 mg #	#30	First 5 days: 1 cap
1	-2 QAM AD	Second 5 days: 2 caps
		Third 5 days: 3 caps

COMBINATION THERAPY

• Length of action insufficient?

- Addition of IR formulation
 Ascending drug plasma level to maintain
 - efficacy
 - Utilize same basic agent
- Daytrana patch
- Intolerable adverse effects at higher doses?
- Change stimulant for monotherapy
- Addition of alpha-agonist
- Strattera as mono or combination therapy



Managing Adverse Events

- Appetite loss & Growth delay
- Headache, Stomachache, Nausea
- Mood lability & Irritability
- Rebound hyperactivity • Sleep difficulties
- Psychosis
- Suicidality
- Priapism
- o Tics

Discontinuing Medication

- Persistence of symptoms?
- Scheduled breaks and monitoring of symptoms (Winter/Summer breaks, etc.)
- Individualized approach
- Medication can always be restarted
- More easily with stimulants

Other Target Symptoms in ASD

- Disruptive behaviors and irritability
- Repetitive behaviors and rigidity
- Depression and anxiety
- Mood disorders and psychosis
- Sleep disturbance

Disruptive Behavior Disorders and Irritability: Atypical **Neuroleptics**

- Two medications FDA approved for irritability in ASD
- Risperidone (>5): most commonly used, effective in clinical trials (2002)
- Aripiprazole (>6): effective in trials (2009) • Other agents
- - Olanzapine, quetiapine: metabolic issues • Ziprasidone, lurasidone: less evidence but maybe better metabolic profile

Disruptive Behavior Disorders and Irritability: Atypical Neuroleptics

- Adverse effects of atypical neuroleptics
 - Sedation, weight gain, hypercholesterolemia, diabetes, tremor, EPS and akithesia, hyperprolactinemia
- Baseline evaluation
- Lab work, weight, AIMS, EKG, vital signs
- Lab: CBC, CMP, prolactin, Lipids, HgbA1C
- Routine monitoring of above

Disruptive Behavior Disorders and Irritability: Typical (1stgeneration) Neuroleptics

- Haloperidol, chlorpromazine and others
- Often used as either standing medication or as-needed (PRN) medication
- Adverse effects
 - Some similar to atypicals but often attenuated
 - Extrapyramidal symptoms, tardive dyskinesia and neuromalignant syndrome

Disruptive Behavior Disorders and Irritability: Other agents

- Alpha agonists, mood stabilizers, SSRIs, beta-blockers
- Continuously reevaluate cause of symptoms
- Medical issues: constipation, infection, dental caries
- ${\scriptstyle \circ}$ Depression, anxiety (SSRIs)
- Communication issues

Repetitive Behaviors and Rigidity

- Assessment of benefits v. risks of treatment
- Marginal evidence of pharmacological benefit
- Agents
- SSRIs
- Clomipramine
- Atypical neuroleptics and Depakote
- Ineffective in trial: naltrexone, stimulants (Huffman 2011)

Repetitive Behaviors and Rigidity: SSRIs

- Relatively few side effects
- Can help with concurrent depressive and anxious symptoms
- Fluoxetine: 2 recent studies suggest efficacy (Hollander 2005 and 2012)
- Citalopram: 2009 study ineffective (King et al)
 Fluvoxamine, sertraline, paroxetine,
- escitalopram: studies suggest improvement
- Black box warning re: suicidal ideation

Repetitive Behaviors and Rigidity: Other Agents

- Clomipramine: serotonin-selective TCA, inconsistent findings (Hurwitz 2012)
- Risperidone: one study showed support (McDougle 2005)
- Valproic acid (Depakote): one small, blinded RCT showed improvement (Hollander 2006)

Depression & Anxiety

- Both common in ASD: how to assess?
- Role of therapy and psychosocial interventions
- Can contribute to SIB or aggression
- Same agents as used in non-ASD patients (few studies in ASD)
 - SSRIs, SNRIs: lower doses
- Buspirone: one open-label study in ASD (Buitelaar 1998)

Mood Disorders & Psychotic Disorders

- Important to continually assess into adulthood
- Mania: lithium, atypical neuroleptics, benzodiazepines
- Psychosis: Typical or atypical neuroleptics
- Case examples:
 - 17 y/o female with ASD and mania
 - 23 y/o MTF TG with ASD and psychosis

Sleep Disturbance in ASD

• Extremely common

- Abnormalities in melatonin, serotonin and GABA
- Etiology?
- Sleep hygeine
- Obstructive sleep apnea
- Depression

Sleep Disturbance in ASD: Treatment

• Melatonin

- Most evidence for efficacy (Wright 2011 and Guenole 2011)
- Short-term efficacy of initiation and maintenance
- 3-5 mg dose to start, given 60-90 minutes prior to bedtime
- AEs: daytime sleepiness and enuresis
- OTC, not monitored by FDA: ask pharmacist

Sleep Disturbance in ASD: Treatment

- Trazodone
- Clonidine and guanfacine
- Quetiapine
- Diphenhydramine
- Zolpidem, Ramelteon, benzodiazepines, mirtazapine

Neuropsychological & Mind-**Body Therapies**

- Cognitive training
- EEG Neurofeedback & Biofeedback
- Acupuncture
- Chiropractic Adjustment • Exercise
- Exercise
 Interactive Metronome Training
 Meditation/Mindfulness/Yoga/Massage
- Repetitive TMS
- Sensory Integration Training • Vision Therapy

